Market Trends of Vaccine Contract Development And Manufacturing Organization Industry
The Inactivated Vaccines Segment is Expected to Witness Significant Growth Between 2024 and 2029
Manufacturing inactivated vaccines involve complex steps requiring specialized facilities, expertise, and adherence to stringent quality standards. Inactivated vaccines often rely on growing large quantities of the target virus in a controlled environment. This requires expertise in cell culture techniques and maintaining a sterile and controlled production environment. CDMOs assist by providing state-of-the-art biomanufacturing facilities, skilled personnel, and expertise in cell culture techniques. They have the infrastructure and experience to optimize cell culture processes for efficient virus propagation.
In addition, the virus must be inactivated after propagation to render it non-infectious while retaining its immunogenic properties. This step requires precise control over the inactivation process and subsequent purification to remove any residual live virus. CDMOs have the equipment and expertise to perform inactivation and purification steps in compliance with regulatory standards. They employ advanced techniques to ensure the safety and potency of the final vaccine product. Hence, due to the complex manufacturing process of inactivated vaccines, which requires CDMO experts, they will likely contribute to the market growth between 2024 and 2029.
The collaboration between pharmaceutical companies and CDMOs can lead to research, development, and manufacturing collaborations. This can result in accelerated timelines and improved efficiency in vaccine production. For instance, in January 2022, Novavax, Clover, and Medicago are promising, as is the inactivated vaccine in development by Valneva. They are all in phase III or II/III and have strong investor interest. Novavax’s phase III trials showed an efficacy of 90%, and the company has initiated a pediatric expansion of the phase III trial. Additionally, in November 2022, Valneva SE, a specialty vaccine company, and IDT Biologika announced their collaboration to produce Valneva’s inactivated COVID-19 vaccine candidate VLA2001.
The complexities of inactivated vaccine manufacturing processes and the strategic maneuvers of industry participants are predicted to fuel the segment's growth from 2024 to 2029, propelling market expansion.
North America is Expected to Hold a Significant Market Share Between 2024 and 2029
The increasing adoption of highly advanced techniques and systems in vaccine manufacturing and the technological advancements in vaccine research and development are expected to boost the market's growth in North America. The high awareness among the population about the availability of vaccines, the expansion of facilities by the CDMO companies, and collaboration and partnership activities in the market contribute to the high market growth in the region.
The expansion of vaccine manufacturing plants by the CDMO players is expected to boost the market between 2024 and 2029. For instance, in October 2022, Fujifilm Diosynth Biotechnologies initiated its single-use production campus expansion project in College Station, Texas. The project has involved setting up a new cGMP production facility to become operational by 2024 and create 150 skilled job opportunities. The expansion aims to double the company's vaccine manufacturing capacity in the United States.
In addition, government agencies may provide incentives, grants, or streamlined regulatory processes to encourage the growth of the vaccine manufacturing sector. For instance, in July 2023, Emergent BioSolutions Inc. a CDMO received US Food and Drug Administration (FDA) approved CYFENDUS\ (Anthrax Vaccine Adsorbed, Adjuvanted), previously known as AV7909, for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis in people between 18 and 65 years of age when administered in conjunction with recommended antibacterial drugs.
Furthermore, the collaboration and partnership agreement by CDMOs with the pharmaceutical companies to streamline vaccine manufacturing and development is expected to contribute to market growth. For instance, in May 2023, Moderna, Inc. announced a long-term agreement with Ontario-based Novocol Pharma, a CDMO, to perform aseptic fill-finish, labeling, and packaging of mRNA respiratory vaccines expected to be produced in Canada.
Thus, the expansion of vaccine facilities by CDMO, along with strategic collaboration, is expected to boost the market in North America between 2024 and 2029.
